Fredun Pharmaceuticals Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Fredun Pharmaceuticals Ltd filed with BSE on 12 Jun 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Fredun Pharmaceuticals reported Q4 FY26 total income of INR213 crores, up 27.27% year-on-year, with EBITDA of INR29.13 crores and net profit of INR11.07 crores. For FY26, total income reached INR639.12 crores, a 40.08% year-on-year increase, with EBITDA of INR94.79 crores and net profit of INR33.21 crores. Management discussed growth plans for its hormonal, anti-aging, mobility, and pet care businesses, and addressed questions on raw material costs, finance costs, margins, and working capital.
Numbers mentioned
Total income: INR213 crores (Q4 FY26)
p. 3
“During the Q4 FY '26 total income stood at INR213 crores, which is a strong growth of 27.27% yearon-year compared to INR167.41 crores in Q4 FY '25.”
Sakhi Panjiyara, page 3 of the filed PDF · View the filing
EBITDA: INR29.13 crores (Q4 FY26)
p. 3
“EBITDA comes in at INR29.13 crores, reflecting a robust growth of 67.05% year-on-year, EBITDA margin improved to 13.67%, expanding by 326 basis points.”
Sakhi Panjiyara, page 3 of the filed PDF · View the filing
Net profit: INR11.07 crores (Q4 FY26)
p. 3
“Net profit for the quarter stood at INR11.07 crores with a growth of 56.47% year-on-year.”
Sakhi Panjiyara, page 3 of the filed PDF · View the filing
Net profit margin: 5.19% (Q4 FY26)
p. 3
“Net profit margin improved to 5.19% expended by 97 basis points.”
Sakhi Panjiyara, page 3 of the filed PDF · View the filing
Total income: INR639.12 crores (FY26)
p. 3
“For FY '26, the total income reached INR639.12 crores, marking of 40.08% year-on-year growth.”
Sakhi Panjiyara, page 3 of the filed PDF · View the filing
EBITDA: INR94.79 crores (FY26)
p. 3
“EBITDA stood at INR94.79 crores, up by 72.05% year-on-year.”
Sakhi Panjiyara, page 3 of the filed PDF · View the filing
EBITDA margin: 14.83% (FY26)
p. 3
“EBITDA margin improving to 14.83% and expansion of 276 basis points.”
Sakhi Panjiyara, page 3 of the filed PDF · View the filing
Net profit: INR33.21 crores (FY26)
p. 3
“Net profit increased to INR33.21 crores, delivering a strong 59.59% growth year-on-year.”
Sakhi Panjiyara, page 3 of the filed PDF · View the filing
Mobility division revenue: around INR30 crores (prior year)
p. 5
“Last year, we did around almost INR30 crores of mobility products.”
Fredun Medhora, page 5 of the filed PDF · View the filing
Order book: INR320 crores to INR330 crores
p. 8
“This time also, we have orders upwards of INR320 crores, INR330 crores in hand.”
Fredun Medhora, page 8 of the filed PDF · View the filing
Pet Care business sales: INR42 crores to INR43 crores (FY26)
p. 9
“We have done around INR42 crores, INR43 crores of sale in the Pet Care business.”
Fredun Medhora, page 9 of the filed PDF · View the filing
Mobility business sales: INR29 crores to INR30 crores (FY26)
p. 9
“In the mobility, we have done around INR29 crores to INR30 crores.”
Fredun Medhora, page 9 of the filed PDF · View the filing
Nutraceuticals sales: around INR26 crores (FY26)
p. 9
“We have done nutraceuticals of around INR26 crores.”
Fredun Medhora, page 9 of the filed PDF · View the filing
Debt-to-equity ratio: 0.8
p. 15
“Debt-toequity is 0.8.”
Fredun Medhora, page 15 of the filed PDF · View the filing
Historical CAGR: 32% (last 19 years)
p. 12
“Last 19 years, our growth is a 32% CAGR.”
Fredun Medhora, page 12 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Mobility division revenue — INR100 crores run rate · 2 to 2.5 years
stated as an aspiration by Fredun Medhora
p. 5
“We do not foresee any problem in touching INR100 crores within a 2 to 2.5 years from now, calendar 2.5 calendar years from now and INR100 crores run rate.”
Fredun Medhora, page 5 of the filed PDF · View the filing
Mobility division revenue — INR250 crores to INR300 crores · 5 to 7 years
stated as an aspiration by Fredun Medhora
p. 5
“We are looking at easily within the next 5 to 7 years, INR250 crores to INR300 crores enterprise coming out of this.”
Fredun Medhora, page 5 of the filed PDF · View the filing
Mobilitics brand revenue — INR30 crores to INR40 crores · next 2 years
stated as an aspiration by Fredun Medhora
p. 6
“Hopefully, that alone should go into INR30 crores to INR40 crores in the next 2 years, just the Mobilitics part of Fredun Mobility.”
Fredun Medhora, page 6 of the filed PDF · View the filing
Top line growth — 25% to 30% · FY27
stated firmly by Fredun Medhora
p. 9
“We can consider a growth and overall growth of around 25% to 30% on our top line from the last year.”
Fredun Medhora, page 9 of the filed PDF · View the filing
New age vs vintage business mix — 50% each · next few years
stated as an aspiration by Fredun Medhora
p. 9
“So we definitely will keep on growing the new age business also within the next few years, that will -- the percentage of the business will come to around 50% each.”
Fredun Medhora, page 9 of the filed PDF · View the filing
New age vs vintage business mix — 70% to 30% · 2 to 3 years after reaching 50-50
stated as an aspiration by Fredun Medhora
p. 9
“And within the next 2, 3 years post that, it will be around 70% to 30%.”
Fredun Medhora, page 9 of the filed PDF · View the filing
Business model transition to consumer products — next 7 to 8 years
stated as an aspiration by Fredun Medhora
p. 9
“So we are not intrinsically a pharmacy anymore we are a mass market consumer product company as we speak, and we are growing.”
Fredun Medhora, page 9 of the filed PDF · View the filing
PAT margin — 10% to 12% · next few years
stated as an aspiration by Fredun Medhora
p. 12
“So, within the next few years, you're easily looking 10% to 12% PAT kind of company on a 2x, 3x kind of top line within the next few years.”
Fredun Medhora, page 12 of the filed PDF · View the filing
Manufacturing packing lines addition — 12 to 13 packing lines · by end of September
stated firmly by Fredun Medhora
p. 14
“Even as we speak, we are adding another 12 to 13 packing lines by end of September.”
Fredun Medhora, page 14 of the filed PDF · View the filing
Manufacturing plant ranking — top 3, top 4 manufacturing plants · next 2.5 years
stated as an aspiration by Fredun Medhora
p. 14
“even right now within the next 2.5 years, we should be in the top 3, top 4 manufacturing plants for capacities at a certain location.”
Fredun Medhora, page 14 of the filed PDF · View the filing
Wagr.in platform launch — next 35 to 40 days
stated firmly by Fredun Medhora
p. 13
“Hopefully, you will be able to see it in the next 35, 40 days active and live.”
Fredun Medhora, page 13 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management described the hormonal and anti-aging lines as fragmented, high-margin, underserved markets where the company holds first-mover advantages including exclusive API import rights for NAD+.
Answered by Fredun Medhora
Asked by Keshav Toshniwal: How does management view the newly launched hormonal and anti-aging product lines and plans for them?
p. 4
“We are one of the first manufacturers for NAD, NAD+. We are one of the first ones to have exclusive import rights for the API also, which is right now the talk of the town.”
Fredun Medhora, page 4 of the filed PDF · View the filing
Management said the Mobility division leverages the company's existing pharma distribution network across chemist shops, giving it an advantage over standalone mobility brands, and expects strong growth.
Answered by Fredun Medhora
Asked by Vinod Shah: What is the growth strategy for the Mobility division?
p. 5
“Companies like Visco and Timo don't have pharma along to sell it. We have -- that gives us an upper hand the distribution that gives us an upper hand in even logistics, which is a big component when it comes to mobility products like wheelchairs and walkers and so on and so forth.”
Fredun Medhora, page 5 of the filed PDF · View the filing
Management said buffer stock of 3-4 months insulated them from the initial price shock and that any cost increase has had almost no impact on margins, while sales actually increased.
Answered by Fredun Medhora
Asked by Ankit: Have raw material costs risen due to Middle East geopolitical tensions and is the company able to pass these on?
p. 7
“But there in because we always used to keep 3 to 4 months of stock, that initial jolt of that price increase never bothered us.”
Fredun Medhora, page 7 of the filed PDF · View the filing
Management gave segment-wise revenue figures, noting new-age businesses are growing 40-50% CAGR from a smaller base while vintage grows 10-15%.
Answered by Fredun Medhora
Asked by Nikhil Agarwal: What is the revenue breakup between vintage and new-age businesses in FY26?
p. 9
“So we are doing quite well. The new age businesses are growing at around 40% to 50% CAGR because they are coming from a smaller base.”
Fredun Medhora, page 9 of the filed PDF · View the filing
Management guided to 25-30% top-line growth for the year, describing this as an achievable and on-track target.
Answered by Fredun Medhora
Asked by Nishita Shanklesha: Can management quantify the overachievement expected in FY27?
p. 10
“We are on track to do it. And our numbers as we speak and the run rate, as we speak, are in line to achieve that.”
Fredun Medhora, page 10 of the filed PDF · View the filing
Management acknowledged awareness of finance costs and said the percentage cost of debt should improve over the next 3-4 years as credit rating and balance sheet improve.
Answered by Fredun Medhora
Asked by Keshav Toshniwal: Is management aware of the rising finance costs given increased debt levels?
p. 11
“But within the next 3 to 4 years, you will see a pretty different picture when it comes to this in terms of your percentage of the spend.”
Fredun Medhora, page 11 of the filed PDF · View the filing
Management attributed margin improvement to economies of scale in the vintage business and higher intrinsic margins in new-age businesses, expecting a spike in profitability once new-age demographic reach is saturated.
Answered by Fredun Medhora
Asked by Nishita Shanklesha: What is driving the margin improvement and what are sustainable margins going forward?
p. 12
“Our margins have improved because since 2016, I have been saying post INR50 crores a quarter revenue, the economies of scale in the vintage business will start hitting in and that is exactly what happened in 2021, 2022.”
Fredun Medhora, page 12 of the filed PDF · View the filing
Management said around 80% of products are manufactured in-house across roughly 43 locations, with capacity being expanded via new packing lines and a new plant wing.
Answered by Fredun Medhora
Asked by Nikhil Agarwal: What is the manufacturing capacity utilization and split between in-house and outsourced production?
p. 14
“Right now, I would say about 80% of our products or more than 80% gets manufactured in-house.”
Fredun Medhora, page 14 of the filed PDF · View the filing
Management said inventory levels relative to revenue have improved significantly over the years and that operating cash flows have turned positive after a planned period of strain.
Answered by Fredun Medhora
Asked by Devang Shah: Is there concern about working capital requirements and free cash flow, and what is the plan to utilize cash effectively?
p. 15
“Now the cash flows have improved, we have positive cash flows even from our operations as we speak.”
Fredun Medhora, page 15 of the filed PDF · View the filing
Risks flagged
Global oil and petroleum-linked input price increases affecting raw material costs
p. 8
“The oil prices have increased globally, the PVC price, plastic prices have increased, anything to do with petroleum as it is globally.”
Fredun Medhora, page 8 of the filed PDF · View the filing
Some cost increases have to be absorbed by the company on certain products
p. 8
“Few percentage, 1% or 2%, the buyer absorbs sometimes certain products we have to absorb, but it has absolutely no difference to our bottom line.”
Fredun Medhora, page 8 of the filed PDF · View the filing
Working capital requirements may increase as the company continues to grow
p. 15
“We will -- we might require more debt. We might require more working capital as we are growing.”
Fredun Medhora, page 15 of the filed PDF · View the filing
Pharma industry is subject to cyclicality
p. 12
“Pharma definitely will have its cycles.”
Fredun Medhora, page 12 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.